Chris Hoy calls for systemic change in testing for prostate cancer
Six-time Olympic champion Sir Chris Hoy has called for systemic change in the ways men get tested for prostate cancer.
The 49-year old cyclist was diagnosed with stage four prostate cancer in 2023 and was told last year that it has spread to his bones and is terminal.
NHS guidance says men over the age of 50 are at highest risk of developing prostate cancer, but Sir Chris wants to help men get screened earlier.
He said: 'I was diagnosed with stage four prostate cancer at 47. By this age, my prostate cancer was advanced and could have been progressing from when I was 45 or even younger.
'With prostate cancer, the earlier you find it, the easier it is to treat. We need the system to change to enable more men to get diagnosed earlier, and stop them getting the news I got.'
One option is a PSA blood test which checks the level of prostate-specific antigens in the blood, A high reading may be a sign of a prostate condition.
NHS guidance says these tests are not routinely used as they are not reliable, but men over 50 can ask GPs for one.
Sir Chris's comments came after Prostate Cancer UK urged the UK Government for an overhaul of NHS guidelines to encourage GPs to proactively speak to men at high risk from 45 years old.
#ProstateCancer has become the most common cancer in England.
However, for a disease that affects 1 in 8 men, there's still no screening programme and outdated NHS guidelines prevent lifesaving conversations with men at highest risk.
➡️ Read more: https://t.co/wvVi5jbS0P pic.twitter.com/KUh0oY1H0R
— Prostate Cancer UK (@ProstateUK) January 28, 2025
According to the charity, around one in eight men in the UK will get prostate cancer, which occurs when cells in the prostate start to grow in an uncontrolled way and, if not detected early, risks spreading.
Sir Chris added: 'I believe men at highest risk, for example men with a family history like me or black men, should be contacted by their GP earlier on to discuss a simple PSA blood test that can check for signs of prostate cancer. Then if there are any issues, they can get it treated it at an earlier stage.
'I've told my story to help raise awareness about the most common cancer in men and get more thinking about their risk and what they can do, but it shouldn't all be men's responsibility.
'I've faced many challenges in my life, and going public with my prostate cancer diagnosis was certainly one of them.
'I've been incredibly lucky to have so much support from my family, friends and the general public. The kindness has lifted me up and given me a sense of purpose, and I'm committed to taking that forward and using my platform to raise awareness of the most common cancer in men and help more men at risk to come forward and get tested.'
The Scottish cyclist has launched his own charity cycling challenge, Tour de 4, with the aim of changing perceptions around stage four cancer.
The challenge will take place on September 7 in Glasgow with a final registration phase open for riders to sign up.
Speaking about Sir Chris, Laura Kerby, chief executive at Prostate Cancer UK, said: 'His bravery and tireless work to raise awareness has already made a huge impact.
'In just a few months after Sir Chris went public with his diagnosis last year, over 286,000 people used our online risk checker to learn more about the disease, find out their own risk and learn what they can choose to do about it.
'His bravery has inspired so many men to take action, and he has undoubtedly saved lives.
'One in eight men will get prostate cancer. The earlier it's found, the easier it is to treat — but there's currently no screening programme in the UK. So if, like Sir Chris, you have a family history of the disease, or if you're black, we strongly encourage you to speak to your GP about testing from the age of 45.
'We don't think it's right that the responsibility is all on men's shoulders, so we're calling on the Health Secretary to overhaul outdated NHS guidelines so that GPs are empowered to actually start conversations with these men at highest risk.'
A Government spokesperson said: 'This Government has been clear we would like to see screening in place but the decision must be evidence-led, which is why the UK National Screening Committee is looking at this as a priority – including reviewing the evidence for screening men with a family history of prostate cancer.
'While the review is taking place we are getting on with improving cancer treatment and prevention, as well as funding tens of millions of pounds of research.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
30 minutes ago
- Daily Mail
Every newborn baby in the UK will have DNA screening in NHS 'revolution' to battle killer diseases, Wes Streeting reveals
Every newborn baby in the UK will have a DNA screening as part of an NHS 'revolution' to battle killer diseases. The health secretary Wes Streeting said new technology in areas such as genomics would help 'leapfrog' illnesses. The Government is set to pour £650 million into DNA technology in an effort to treat serious illnesses before they become a problem. The investment in genomics is expected to support the Government's 10-year plan for the NHS, which will see a greater focus on technology and prevention. Mr Streeting told The Telegraph: 'The revolution in medical science means that we can transform the NHS over the coming decade, from a service which diagnoses and treats ill health to one that predicts and prevents it. 'Genomics presents us with the opportunity to leapfrog disease, so we're in front of it rather than reacting to it.' Mr Streeting has previously spoken about his desire to make the NHS more preventative, reducing rates of serious illness and saving money in the process. The plan is also likely to see a greater role for artificial intelligence and other technologies to predict illness and allow treatment or medication to be offered much earlier. Mr Streeting has previously spoken about his desire to make the NHS more preventative, reducing rates of serious illness and saving money in the process. The plan is also likely to see a greater role for artificial intelligence and other technologies to predict illness and allow treatment or medication to be offered much earlier. He added: 'With the power of this new technology, patients will be able to receive personalised healthcare to prevent ill health before symptoms begin, reducing the pressure on NHS services and helping people live longer, healthier lives.' Along with a greater focus on prevention, the Government's 10-year plan is expected to include Mr Streeting's two other 'shifts' in the NHS. That will see a shift away from hospitals towards more community-focused care, and from analogue to digital services. It follows Chancellor Rachel Reeves' announcement that the Government would increase NHS funding by £29 billion per year in real terms over the next three years as it tries to cut waiting lists in line with its election promises.
The Independent
38 minutes ago
- The Independent
Weight loss jab could be used to treat migraines
Weight loss jabs could cut the number of migraines sufferers experience by half, research suggests. The drugs, similar to Ozempic and Wegovy, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion. Researchers have discovered, GLP-1 drug liraglutide, commonly used to treat diabetes, has the potential to significantly reduce migraine frequency. Migraines affect approximately 6 million people in the UK, according to the NHS. Attacks can last for three days causing pain, nausea, vomiting, dizziness and sensitivity to light, sound and smells. Researchers at the Headache Centre of the University of Naples gave 26 adults with obesity and chronic migraines the drug liraglutide. The study presented at the European Academy of Neurology (EAN) Congress 2025, found those who had the drug reported an average of 11 fewer headache days per month. Participants also experienced meaningful improvements in quality of life, work, study, and social functioning within just two weeks of taking the drug. 'Most patients felt better within the first two weeks and reported quality of life improved significantly', said lead researcher Dr Simone Braca. 'The benefit lasted for the full three-month observation period, even though weight loss was modest and statistically non-significant.' Growing evidence has linked subtle increases in intracranial pressure to migraine attacks. It's caused by a rise in the pressure of cerebrospinal fluid – which surrounds the brain and spinal cord. This increase in pressure can happen because of a severe head injury, stroke, a brain tumour or high blood pressure. But GLP-1-receptor agonists such as liraglutide reduce cerebrospinal fluid secretion and have already proved effective in treating idiopathic intracranial hypertension (IIH). Patients in the study were screened to exclude papilledema (optic disc swelling resulting from increased intracranial pressure) and sixth nerve palsy, ruling out IIH. Dr Braca and colleagues believe GLP-1 drugs may reduce the release of CGRP (calcitonin gene-related peptide), a key molecule behind migraines. 'We think that, by modulating cerebrospinal fluid pressure and reducing intracranial venous sinuses compression, these drugs produce a decrease in the release of calcitonin gene-related peptide (CGRP), a key migraine-promoting peptide', Dr Braca said. 'That would pose intracranial pressure control as a brand-new, pharmacologically targetable pathway.' Given liraglutide's established use in type 2 diabetes and obesity, it may represent a promising case of drug repurposing in neurology, study authors said.
The Guardian
an hour ago
- The Guardian
All babies in England to get DNA test to assess risk of diseases within 10 years
Every baby in England is to have a DNA screening to avoid fatal diseases and receive personalised healthcare as part of the government's £650m investment in DNA technology, it has been reported. Within a decade, every newborn will undergo whole genome sequencing, which assesses the risk of hundreds of diseases and is expected to form part of the government's 10-year plan for the health service. Wes Streeting, the health secretary, told the Telegraph the advances in genomics would allow people to 'leapfrog' killer illnesses and receive 'personalised' health care. He said: 'The revolution in medical science means that we can transform the NHS over the coming decade, from a service which diagnoses and treats ill health to one that predicts and prevents it. 'Genomics presents us with the opportunity to leapfrog disease, so we're in front of it rather than reacting to it.' Streeting added: 'With the power of this new technology, patients will be able to receive personalised healthcare to prevent ill health before symptoms begin, reducing the pressure on NHS services and helping people live longer, healthier lives.' All new parents are now offered a blood spot test for their babies, normally when the child is five days old, to check whether they have any of nine rare but serious conditions. The newborn's heel is pricked to collect a few drops of blood on a card that is sent away to be tested. Along with a greater focus on prevention, the 10-year plan is expected to include Streeting's other 'shifts' in the NHS, from hospitals towards more community-focused care and from analogue to digital services. Last week the chancellor, Rachel Reeves, announced that the government would increase NHS funding by £29bn a year in real terms over the next three years. A Department of Health and Social Care spokesperson said: 'Our 10-year health plan will be published soon and will set out details for a range of initiatives to advance the NHS and make it fit for the future.' In October, the NHS in England announced it was to screen 100,000 newborn babies for more than 200 genetic conditions in a world-first scheme aimed at bolstering early diagnosis and treatment.
